Acorda (ACOR) CEO On CNBC
Down)
Acorda Therapeutics, Inc. (Nasdaq: ACOR) CEO Ron Cohen is speaking on CNBC now about this morning's deal with Biogen Idec (Nasdaq: BIIB) to commercialize MS Therapy Fampridine-SR in Markets Outside the U.S.
While the stock is down 11.6% on the news, Cohen calls it a "great deal."
CNBC reporter Mike Huckman suggests there may be some disappointment that it wasn't a buyout, about the terms of the deal, or are selling after the recent run-up. Cohen said he can't explain the stock reaction to the news.
While the stock is down 11.6% on the news, Cohen calls it a "great deal."
CNBC reporter Mike Huckman suggests there may be some disappointment that it wasn't a buyout, about the terms of the deal, or are selling after the recent run-up. Cohen said he can't explain the stock reaction to the news.
You May Also Be Interested In
- Canaccord Genuity Reiterates a 'Buy' on InterMune Inc. (ITMN); Esbriet (pirfenidone) Positive GBA Assessment
- Perrigo (PRGO) Gets Final FDA Approval for Generic Prevacid Caps (NVS)
- Pre-Open Movers 5/18: (PSUN) (WGO) (CRM) Higher; (ADSK) (SQNM) (ARUN) Lower (more...)
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
